As well-established in the literature, the PI3K/Akt and p53 signaling pathways play central roles in tumor regulation; however, targeted therapeutic options for gastric cancer within these pathways remain sparse, with drug development proving to be challenging. This evidence concerns the gene AKT1 and gastric cancer.